Aster DM Healthcare Limited

INR 6,491

: 12.4 Mn India : 2.2 Mn4 Largest Number of Medical Centers/Polyclinics 8,671 Cr Revenue5 GCC : INR 6,491 Cr India : INR 2,179 Cr 828 Total Facilities Net Unit Additions in FY23 Q3 Total : 37 Pharmacies |

INR 2,179

2 Mn4 Largest Number of Medical Centers/Polyclinics 8,671 Cr Revenue5 GCC : INR 6,491 Cr India : INR 2,179 Cr 828 Total Facilities Net Unit Additions in FY23 Q3 Total : 37 Pharmacies | 4 Clinics | 1 Satel

rs6

Patient Experience Centers One of the Largest Chain of Pharmacies 29,108* Human Resources Doctors6 : 3,820 : 8,299 Nurses Others7 : 13,102 Outsourced7 : 3,887 Geographical Footprint 6 United Arab

rs7

of the Largest Chain of Pharmacies 29,108* Human Resources Doctors6 : 3,820 : 8,299 Nurses Others7 : 13,102 Outsourced7 : 3,887 Geographical Footprint 6 United Arab Emirates H(9) C(99) P(234) Kin

Rs. 3,161

and Profitability Snapshot – FY23 Q3 Revenue from Operations ▪ Revenue excluding new hospitals4 is Rs. 3,161 Crs. (Growth of 19 %) ▪ EBITDA (excl. Other Income) EBITDA excluding new hospitals4 is Rs. 468 Crs

19 %

– FY23 Q3 Revenue from Operations ▪ Revenue excluding new hospitals4 is Rs. 3,161 Crs. (Growth of 19 %) ▪ EBITDA (excl. Other Income) EBITDA excluding new hospitals4 is Rs. 468 Crs. (Growth of 15%, EB

Rs. 468

Rs. 3,161 Crs. (Growth of 19 %) ▪ EBITDA (excl. Other Income) EBITDA excluding new hospitals4 is Rs. 468 Crs. (Growth of 15%, EBITDA Margin of 14.8%) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospita

15%

of 19 %) ▪ EBITDA (excl. Other Income) EBITDA excluding new hospitals4 is Rs. 468 Crs. (Growth of 15%, EBITDA Margin of 14.8%) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 180 Crs.

14.8%

xcl. Other Income) EBITDA excluding new hospitals4 is Rs. 468 Crs. (Growth of 15%, EBITDA Margin of 14.8%) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 180 Crs. (Growth of 12 %, EBITDA

Rs. 180

rowth of 15%, EBITDA Margin of 14.8%) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 180 Crs. (Growth of 12 %, EBITDA Margin of 5.7%) ▪ GCC Revenue for FY23 Q3 includes Covid Testing and v

12 %

gin of 14.8%) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 180 Crs. (Growth of 12 %, EBITDA Margin of 5.7%) ▪ GCC Revenue for FY23 Q3 includes Covid Testing and vaccination income of

5.7%

t-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 180 Crs. (Growth of 12 %, EBITDA Margin of 5.7%) ▪ GCC Revenue for FY23 Q3 includes Covid Testing and vaccination income of Rs. 17 Crs ; this was

Source

1

Source

1. english.alarabiya.net 2. worldpopulationreview.com 3. 4. omanobserver.com edsfze.com (INDIA) t n e r r u C s u t a t S ◼ ◼ ◼ ◼ y a W d r a w r o F ◼ ◼ ◼ ◼ *239 pharmacies in India operated by ARPPL under brand license from Aster Aster - Awards & Service Excellence 20 Dr. Azad Moopen • • • • • Alisha Moopen • • • • • • 6 JCI Accredited Aster Hospital Mankhool, Qusais and Day Care Surgery Centre in UAE “Saudi Central Board for Accreditation for Healthcare Institutions (CBAHI)” DNV Accreditation – Orthopaedics Centre of Excellence Accreditation from European Society of Medical Oncology NABH and NABL Accreditations JCI Accredited HIMMS Accreditation (Stage 6) Aster Mankhool SRV Accreditation - Endometriosis Aster - Awards UAE Innovation Award Dubai Quality Award DQA - DQAA Times All India Multispecialty Hospitals Ranking Survey 2021 IHF ICC Healthcare Excellence Awards The Economics Times Healthcare Awards World Stroke Association Rating Newsweek World’s Best Hospitals International Bes